GlassScriptPhysician profile
Raphaella V Daggett
NPI 1922529098
$6,116.92
in general payments reported to CMS, 2019-2025
56 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $1,138 · 2023: $1,514 · 2024: $1,362 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,810 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,809.85 |
| Education | $388.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $641.65 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $394.23 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Astellas Pharma US INC | $390.14 | 2021-2025 | Xospata, Padcev |
| Abbvie INC. | $323.65 | 2021-2025 | |
| Pfizer INC. | $322.56 | 2021-2025 | |
| Incyte Corporation | $298.11 | 2021-2025 | Jakafi |
| Rigel Pharmaceuticals, INC. | $278.68 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Celgene Corporation | $275.67 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $264.23 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $241.39 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $174.85 | 2021-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $141.50 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Glaxosmithkline, LLC. | $130.62 | 2024-2025 | Ojjaara |
| Eisai INC. | $124.52 | 2022-2025 | |
| Genzyme Corporation | $119.62 | 2021-2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $117.71 | 2021-2024 | Verzenio |
| Pharmaessentia USA Corporation | $114.71 | 2022-2025 | Besremi |
| Janssen Pharmaceuticals, INC | $113.94 | 2021-2023 | Xarelto |
| Aveo Pharmaceuticals, INC. | $112.34 | 2021-2023 | Fotivda |
| Array Biopharma INC | $103.09 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $96.42 | 2021-2025 | Tecentriq, Phesgo, Perjeta |
| Ipsen Biopharmaceuticals, INC | $95.09 | 2021-2025 | Onivyde |
| Amgen INC. | $92.63 | 2021-2023 | Lumakras, Kyprolis, Vectibix |
| Stemline Therapeutics INC. | $89.23 | 2023-2025 | Orserdu, Elzonris |
| Coherus Oncology, INC. | $87.99 | 2022-2025 | Loqtorzi |
| Takeda Pharmaceuticals U.S.A., INC. | $86.20 | 2021-2025 | Iclusig, Alunbrig, Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $76.75 | 2024-2025 | Opdivo, Opdualag |
| Seagen INC. | $69.22 | 2022-2023 | Adcetris |
| Gilead Sciences, INC. | $66.06 | 2022-2025 | Trodelvy |
| Emd Serono, INC. | $65.62 | 2023-2024 | Bavencio |
| Adc Therapeutics America, INC. | $51.02 | 2022-2025 | |
| Beigene USA, INC. | $49.05 | 2021-2024 | Brukinsa |
| Exelixis INC. | $46.28 | 2025 | Cabometyx |
| Mirati Therapeutics, INC. | $40.46 | 2023-2024 | Krazati |
| Taiho Oncology, INC. | $31.01 | 2025 | |
| Morphosys, US INC. | $28.90 | 2022-2023 | Monjuvi |
| Iovance Biotherapeutics, INC. | $28.72 | 2025 | Amtagvi |
| Geron Corporation | $28.35 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $22.02 | 2025 | |
| Organon LLC | $21.31 | 2023 | Ontruzant |
| Karyopharm Therapeutics INC. | $20.10 | 2025 | Xpovio |
| Cti Biopharma Corp. | $19.84 | 2023 | Vonjo |
| Recordati_rare_diseases_inc. | $18.74 | 2025 | Enjaymo |
| Foundation Medicine, INC. | $18.58 | 2022 | |
| Sobi, INC | $18.34 | 2023 | |
| Jazz Pharmaceuticals INC. | $17.71 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.60 | 2021 | |
| Epizyme, INC. | $17.45 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.67 | 2023 | Yonsa, Odomzo |
| Myriad Genetic Laboratories, INC. | $15.49 | 2022 | |
| Amag Pharmaceuticals, INC. | $14.55 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.03 | 2022 | |
| Agios Pharmaceuticals, INC. | $13.79 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $13.64 | 2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $12.76 | 2023 | Libtayo |
| Dova Pharmaceuticals | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphaella Daggett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.